Nov. 9 (Reuters) – Inovio Pharmaceuticals Inc (INO.O) said Tuesday that the US Food and Drug Administration (FDA) has lifted a partial clinical hold on the late-stage trial of its COVID-19 vaccine in the country.
Inovio said it is now cleared to continue the trial after 14 months, pushing its shares up 4.6% before the bell.
The FDA postponed its final-stage trial in September last year as it sought more information from the company, including details about a delivery device used to inject genetic material into cells.
Following the decision, the US government withdrew funding for the late-stage study for Inovio’s vaccine, as other COVID-19 vaccines were already available in the country.
Inovio then began late-stage trials outside the United States in collaboration with China’s Advaccine Biopharmaceuticals.
The company is currently conducting the Phase 3 portion of its mid- to late-stage trial in several regions, including Latin America, Asia-Pacific and Africa.
Reporting by Manas Mishra and Dania Nadeem in Bengaluru; Editing by Aditya Soni and Shinjini Ganguli
Our Standards: The Thomson Reuters Trust Principles.